Pyxis Diagnostics
Ari Tadmor is a seasoned professional in the biotechnology and diagnostics sectors, currently serving on the Scientific Advisory Board of Luma Biophotonics, which specializes in photonic integrated circuits for biosensing applications. Previously, Ari was the Chief Executive Officer of Pyxis Diagnostics, focusing on biomarkers for immunotherapy response prediction, and held the same position at ADOR Diagnostics, where the company advanced molecular biology technology for rapid infectious disease diagnosis. Ari also founded Essence Scientific eTools, acted as Chief Technology Officer at Amnionics Medical developing non-invasive amniotic fluid analysis, and served as a Principal Consultant for Tamuz Bioscience, providing due diligence in life sciences. Academic credentials include a Ph.D. in Biology with a focus on immunology and reproductive biology from the Weizmann Institute of Science and a Bachelor's degree in Biotechnology from Hebrew University of Jerusalem.
This person is not in any teams
This person is not in any offices
Pyxis Diagnostics
Immunotherapy revolutionized the treatment of many malignancies. However, many patients fail to respond to immuno-oncology (IO) drugs, although satisfying the accepted clinical criteria for IO treatment. This stems partially from the very incomplete understanding of the network-level interactions between various cells within the tumor itself, which together determine the fate of the anti-cancer immune responses. Using a novel, high-resolution method to resolve all the cells that together comprise the tumour micro-environment, we are able to infer important inter-cellular connections that may protect the tumor from an immune assault. By combining many patient tumor-immune networks, we at Pyxis, can predict IO drug response for many cancer types. Our platform can also suggest alternative treatment routes in cases where the predicted drug response is low, improving the quality of life of oncological patients.